Use of transient elastography (FibroScan®) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients

被引:45
|
作者
Sanchez-Conde, M. [1 ]
Miralles, P. [1 ]
Maria Bellon, J. [2 ]
Rincon, D. [3 ]
Ramirez, M. [1 ]
Gutierrez, I. [1 ]
Ripoll, C. [3 ]
Lopez, J. C. [1 ]
Cosin, J. [1 ]
Clemente, G. [3 ]
Lo Iacono, O. [3 ]
Banares, R. [3 ,4 ]
Berenguer, J. [1 ]
机构
[1] Hosp Gen Univ Gregorio Maranon, Infect Dis & HIV Unit, Madrid, Spain
[2] Hosp Gen Univ Gregorio Maranon, Biomed Res Fdn, Madrid, Spain
[3] Hosp Gen Univ Gregorio Maranon, Hepatol Unit, Madrid, Spain
[4] Spanish CIBERehd Res Grp, Barcelona, Spain
关键词
hepatitis C infection; HIV infection; liver cirrhosis; liver pathology; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; VENOUS-PRESSURE GRADIENT; STAGE LIVER-DISEASE; INFECTED PATIENTS; THERAPEUTIC STRATEGIES; NATURAL-HISTORY; FIBROSIS; CIRRHOSIS; PROGRESSION;
D O I
10.1111/j.1365-2893.2010.01371.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The hepatic venous pressure gradient (HVPG) is the gold standard for assessing portal pressure and correlates with the occurrence of portal hypertension (PH)-related complications. Transient elastography (TE) is a new, highly accurate noninvasive technique, which enables us to evaluate hepatic fibrosis to detect advanced fibrosis and cirrhosis. We performed a hepatic haemodynamic study and TE in 38 HIV/HCV-coinfected patients. The association between HVPG and liver stiffness was assessed by linear regression. The diagnostic value of TE was assessed by receiver operating characteristic (ROC) curves. We considered clinically significant PH as an HVPG >= 10 mmHg and severe PH as an HVPG 12 mmHg. A total of 38 HIV/HCV-coinfected patients were included. Twenty-eight patients (73.7%) had clinically significant PH (HVPG >= 10 mmHg), and 23 (60.5%) of these had severe PH (HVPG >= 12 mmHg). We found a statistically significant association between liver stiffness (kPa) and HVPG(r(2) = 0.46, P < 0.001, straight line equation HVPG = 7.4 + 0.204*TE). The areas under the ROC curves were 0.80 [95% confidence interval (CI), 0.64-0.97] and 0.80 (95% CI, 0.66-0.94) for the prediction of HVPG 10 and 12 mmHg, respectively. Our data suggest that TE can predict the presence of clinically significant and severe PH in HIV/HCV-coinfected patients.
引用
收藏
页码:685 / 691
页数:7
相关论文
共 50 条
  • [41] Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients
    Quereda, Carmen
    Corral, Inigo
    Moreno, Ana
    Perez-Elias, Maria. J.
    Casado, Jose L.
    Dronda, Fernando
    Rodriguez-Sagrado, Miguel A.
    Hernandez, Beatriz
    Moreno, Santiago
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 49 (01) : 61 - 63
  • [42] ACCELERATED FIBROSIS PROGRESSION IN HIV/HCV-COINFECTED PATIENTS UNDER EFFECTIVE ANTIRETROVIRAL THERAPY
    Macias, J.
    von Wichmann, M. A.
    Rivero, A.
    Tellez, F.
    Merino, D.
    Marquez, M.
    Vergara, A.
    Delgado, M.
    Mira, J. A.
    Pineda, J. A.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S412 - S412
  • [43] Update on chronic hepatitis C in HIV/HCV-coinfected patients:: viral interactions and therapy
    Bräu, N
    AIDS, 2003, 17 (16) : 2279 - 2290
  • [44] Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status
    Garcia-Broncano, Pilar
    Maria Medrano, Luz
    Berenguer, Juan
    Gonzalez-Garcia, Juan
    Angeles Jimenez-Sousa, Ma
    Carrero, Ana
    Hontanon, Victor
    Guardiola, Josep M.
    Crespo, Manuel
    Quereda, Carmen
    Sanz, Jose
    Belen Garcia-Gomez, Ana
    Luis Jimenez, Jose
    Resino, Salvador
    CELLS, 2018, 7 (11)
  • [45] Does Early Antiretroviral Treatment Prevent Liver Fibrosis in HIV/HCV-Coinfected Patients?
    Bani-Sadr, Firouze
    Bedossa, Pierre
    Rosenthal, Eric
    Merrien, Dominique
    Perre, Philippe
    Lascoux-Combe, Caroline
    Cacoub, Patrice
    Perronne, Christian
    Pol, Stanislas
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 50 (02) : 234 - 236
  • [46] Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis
    Merchante, Nicolas
    Rivero-Juarez, Antonio
    Tellez, Francisco
    Merino, Dolores
    Jose Rios-Villegas, Maria
    Ojeda-Burgos, Guillermo
    Omar, Mohamed
    Macias, Juan
    Rivero, Antonio
    Perez-Perez, Monserrat
    Raffo, Miguel
    Lopez-Montesinos, Inmaculada
    Marquez-Solero, Manuel
    Amparo Gomez-Vidal, Maria
    Pineda, Juan A.
    AIDS, 2017, 31 (04) : 493 - 500
  • [47] Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012–2014)
    Sonia Vázquez-Morón
    Juan Berenguer
    Juan González-García
    Ma Ángeles Jiménez-Sousa
    Isabel Canorea
    Josep M. Guardiola
    Manuel Crespo
    Carmen Quereda
    José Sanz
    Ana Carrero
    Victor Hontañón
    Ana Avellón
    Salvador Resino
    Scientific Reports, 9
  • [48] Transient rebound of HCV RNA levels among HIV/HCV-coinfected patients early after starting highly active antiretroviral therapy (HAART)
    Rosa, R
    Sanchez-Quijano, A
    Leal, M
    Torronteras, R
    Abad, MA
    Pineda, JA
    Alpanes, E
    Macias, J
    Delgado, J
    Lissen, E
    JOURNAL OF HEPATOLOGY, 2001, 34 : 156 - 156
  • [49] Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy
    Verucchi, G
    Calza, L
    Biagetti, C
    Attard, L
    Costigliola, P
    Manfredi, R
    Pasquinelli, G
    Chiodo, F
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (03) : 326 - 328
  • [50] Lack of relevant pharmacokinetic interaction between raltegravir and ribavirin in HIV/HCV-coinfected patients
    Piedoux, S.
    Piroth, L.
    Solas, C.
    Poizot-Martin, I.
    Montange, D.
    Royer, B.
    Di Martino, V.
    Partisani, M.
    Burty, C.
    Valnet-rabier, M.
    Kantelip, J.
    Muret, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 27 - 27